Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently receiving metformin:
The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution in Administration).
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication helps improve blood sugar control in patients with type 2 diabetes when used alongside diet and exercise. The combination of linagliptin and metformin effectively controls blood sugar, contributing to diabetes management. It is used to reliably maintain patient blood glucose levels.
How to take
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily.
Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily.
1. Patients not currently receiving metformin:
The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution in Administration).
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug.
No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
Precautions
This medication can rarely cause severe lactic acidosis or hypoglycemia, so caution is necessary.
Do not use this medication if you are allergic to any of its components, or if you have type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, acute myocardial infarction, or liver dysfunction.
Due to the risk of hypoglycemia, blood glucose should be closely monitored when taken with insulin or sulfonylureas, and dosage adjustments may be necessary.
Patients with decreased kidney function should regularly check kidney function through blood tests, and this medication should be avoided if kidney function is severely impaired.
During acute infections, dehydration, surgery, or the use of radiocontrast iodine, this medication should be temporarily suspended, and restarted only after stabilizing the condition.
While taking this medication, acute pancreatitis or skin blistering diseases may occur; if abdominal pain or skin abnormalities appear, consult your doctor immediately.
Long-term use may lead to vitamin B12 deficiency, so if symptoms of anemia or neurological issues occur, vitamin B12 levels should be checked.
This medication should be swallowed whole without breaking or chewing the tablets, and the tablet coating may appear in the stool, which is normal.
Use during pregnancy or breastfeeding is not recommended, and if planning to become pregnant, consult a specialist.
Elderly patients often have decreased kidney function, so it is important to carefully check kidney function before and during use, avoiding maximum doses and using appropriate doses.
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly closed container to prevent air or moisture from entering. It is best to store it at room temperature between 1 to 30 degrees Celsius.
Appearance and packaging
Appearance
Oval-shaped extended-release tablet, white to almost white, engraved with LD51 on one side
Package unit
28 tablets/box (7 tablets/PTP x 4)
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.